Biopsychiatry controversy

The biopsychiatry controversy is a dispute over which viewpoint should predominate and form a basis of psychiatric theory and practice. The debate is a criticism of a claimed strict biological view of psychiatric thinking. Its critics include disparate groups such as the antipsychiatry movement and some academics.

Overview of opposition to biopsychiatry

Biological psychiatry or biopsychiatry aims to investigate determinants of mental disorders devising remedial measures of a primarily somatic nature.

This has been criticized by Alvin Pam for being a "stilted, unidimensional, and mechanistic world-view", so that subsequent "research in psychiatry has been geared toward discovering which aberrant genetic or neurophysiological factors underlie and cause social deviance".[1] According to Pam the "blame the body" approach, which typically offers medication for mental distress, shifts the focus from disturbed behavior in the family to putative biochemical imbalances.

Research issues

2003 status in biopsychiatric research

Biopsychiatric research has produced reproducible abnormalities of brain structure and function, and a strong genetic component for a number of psychiatric disorders (although the latter has never been shown to be causative, merely correlative). It has also elucidated some of the mechanisms of action of medications that are effective in treating some of these disorders. Still, by their own admission, this research has not progressed to the stage that they can identify clear biomarkers of these disorders.

Research has shown that serious neurobiological disorders such as schizophrenia reveal reproducible abnormalities of brain structure (such as ventricular enlargement) and function. Compelling evidence exists that disorders including schizophrenia, bipolar disorder, and autism to name a few have a strong genetic component. Still, brain science has not advanced to the point where scientists or clinicians can point to readily discernible pathologic lesions or genetic abnormalities that in and of themselves serve as reliable or predictive biomarkers of a given mental disorder or mental disorders as a group. Ultimately, no gross anatomical lesion such as a tumor may ever be found; rather, mental disorders will likely be proven to represent disorders of intercellular communication; or of disrupted neural circuitry. Research already has elucidated some of the mechanisms of action of medications that are effective for depression, schizophrenia, anxiety, attention deficit, and cognitive disorders such as Alzheimer's disease. These medications clearly exert influence on specific neurotransmitters, naturally occurring brain chemicals that effect, or regulate, communication between neurons in regions of the brain that control mood, complex reasoning, anxiety, and cognition. In 1970, The Nobel Prize was awarded to Julius Axelrod, Ph.D., of the National Institute of Mental Health, for his discovery of how anti-depressant medications regulate the availability of neurotransmitters such as norepinephrine in the synapses, or gaps, between nerve cells.

— American Psychiatric Association, Statement on Diagnosis and Treatment of Mental Disorders[2]

Focus on genetic factors

Researchers have proposed that most common psychiatric and drug abuse disorders can be traced to a small number of dimensions of genetic risk[3] and reports show significant associations between specific genomic regions and psychiatric disorders.[4][5] Though, to date only a few genetic lesions have been demonstrated to be mechanistically responsible for psychiatric conditions.[6][7] For example, one reported finding suggests that in persons diagnosed as schizophrenic as well as in their relatives with chronic psychiatric illnesses, the gene that encodes phosphodiesterase 4B (PDE4B) is disrupted by a balanced translocation.[8]

The reasons for the relative lack of genetic understanding is because the links between genes and mental states defined as abnormal appear highly complex, involve extensive environmental influences and can be mediated in numerous different ways, for example by personality, temperament or life events.[9] Therefore, while twin studies and other research suggests that personality is heritable to some extent, finding the genetic basis for particular personality or temperament traits, and their links to mental health problems, is "at least as hard as the search for genes involved in other complex disorders."[10] Theodore Lidz[11] and The Gene Illusion.[12][13] argue that biopsychiatrists use genetic terminology in an unscientific way to reinforce their approach. Joseph maintains that biopsychiatrists disproportionately focus on understanding the genetics of those individuals with mental health problems at the expense of addressing the problems of the living in the environments of some extremely abusive families or societies.[14]

Focus on biochemical factors

The chemical imbalance hypothesis states that a chemical imbalance within the brain is the main cause of psychiatric conditions and that these conditions can be improved with medication which corrects this imbalance. In that, emotions within a "normal" spectrum reflect a proper balance of neurotransmitter function, but abnormally extreme emotions which are severe enough to impact the daily functioning of patients (as seen in schizophrenia) reflect a profound imbalance. It is the goal of psychiatric intervention, therefore, to regain the homeostasis (via psychopharmacological approaches) that existed prior to the onset of disease.

This conceptual framework has been debated within the scientific community, although no other demonstrably superior hypothesis has emerged. Recently, the biopsychosocial approach to mental illness has been shown to be the most comprehensive and applicable theory in understanding psychiatric disorders. However, there is still much to be discovered in this area of inquiry. As a prime example - while great strides have been made in the field of understanding certain psychiatric disorders (such as schizophrenia)[15] others (such as major depressive disorder) operate via multiple different neurotransmitters and interact in a complex array of systems which are (as yet) not completely understood.

Reductionism

Niall McLaren emphasizes in his books Humanizing Madness and Humanizing Psychiatry that the major problem with psychiatry is that it lacks a unified model of the mind and has become entrapped in a biological reductionist paradigm. The reasons for this biological shift are intuitive as reductionism has been very effective in other fields of science and medicine. However, despite reductionism's efficacy in explaining the smallest parts of the brain this does not explain the mind, which is where he contends the majority of psychopathology stems from. An example would be that every aspect of a computer can be understood scientifically down to the very last atom, however this does not reveal the program that drives this hardware. He also argues that the widespread acceptance of the reductionist paradigm leads to a lack of openness to self-criticism and therefore halts the very engine of scientific progress.[16] He has proposed his own natural dualist model of the mind, the biocognitive model, which is rooted in the theories of David Chalmers and Alan Turing and does not fall into the dualist's trap of spiritualism.[17]

Economic influences on psychiatric practice

American Psychiatric Association president Steven S. Sharfstein, M.D. has stated that when the profit motive of pharmaceutical companies and human good are aligned, the results are mutually beneficial for all. In that, "Pharmaceutical companies have developed and brought to market medications that have transformed the lives of millions of psychiatric patients. The proven effectiveness of antidepressant, mood-stabilizing, and antipsychotic medications has helped sensitize the public to the reality of mental illness and taught them that treatment works. In this way, Big Pharma has helped reduce stigma associated with psychiatric treatment and with psychiatrists." However, Sharfstein acknowledged that the goals of individual physicians who deliver direct patient care can be different from the pharmaceutical and medical device industry. Conflicts arising from this disparity raise natural concerns in this regard including:[18]

  • a "broken health care system" that allows "many patients [to be] prescribed the wrong drugs or drugs they don't need";
  • "medical education opportunities sponsored by pharmaceutical companies [that] are often biased toward one product or another";
  • "[d]irect marketing to consumers [that] also leads to increased demand for medications and inflates expectations about the benefits of medications";
  • "drug companies [paying] physicians to allow company reps to sit in on patient sessions to learn more about care for patients."

Nevertheless, Sharfstein acknowledged that without pharmaceutical companies developing and producing modern medicines - virtually every medical specialty would have few (if any) treatments for the patients that they care for.[18]

Pharmaceutical industry influences in psychiatry

Studies have shown that promotional marketing by pharmaceutical and other companies has the potential to influence physician decision making.[19] Pharmaceutical manufacturers (and other advocates) would argue that in today's modern world - physicians simply do not have the time to continually update their knowledge base on the status of the latest research and that by providing educational materials for both physicians and patients, they are providing an educational perspective[20] and that it is up to the individual physician to decide what treatment is best for their patients. The idea of pure promotion (e.g., lavish dinners) is a remnant of bygone era. It has been replaced by educationally-based activities that became the basis for the legal and industry reforms involving physician gifts, influence in graduate medical education, physician disclosure of conflicts of interest, and other promotional activities.[21]

In an essay on the effect of advertisements for marketed anti-depressants there is some evidence that both patients and physicians can be influenced by media advertisements and this has the possibility of increasing the frequency of certain medicines being prescribed over others.[22]

gollark: Send `{"command": "ping"}` on the `potatoNET` channel on sky`net`.
gollark: `ping` and `settings`, that's it.
gollark: It does some other thing, too...
gollark: Yep.
gollark: Yes.

See also

General

Groups critical of the biomedical paradigm
  • Mindfreedom – A group which advocates "choice" regarding psychopharmaceuticals.
  • ICSPP (International Center for the Study of Psychiatry and Psychology)
  • ISPS (International Society for Psychological and Social Approaches to Psychoses)
  • CEP (Council for Evidence-based Psychiatry)

Criticisms from psychologists and the medical profession
  1. APA Fights Attempt to Limit Access to Psychoactive Drugs, American Psychiatric Association president Michelle Riba, M.D., M.S.
  2. Against Biologic Psychiatry - an article by David Kaiser, M.D., in Psychiatric Times (1996, Vol. XIII, Issue 12).
  3. Challenging the Therapeutic State – special issue of The Journal of Mind and Behavior (1990, Vol.11:3).
  4. Letter of Resignation from the American Psychiatric Association – from Loren R. Mosher, M.D., former Chief of Schizophrenia Studies at the National Institute of Mental Health.
  5. Memorandum from the Critical Psychiatry Network to the United Kingdom Parliament – Written evidence to the House of Commons Select Committee on Health, April 2005.

Methodological issues
  1. On the Limits of Localization of Cognitive Processes in the Brain – an essay by William R. Uttal, Professor Emeritus of Psychology at the University of Michigan, based on his book The New Phrenology (MIT Press, 2001).

References
  1. Pam, Alvin (1995). "Biological psychiatry: science or pseudoscience?". In Colin Ross and Alvin Pam (ed.). Pseudoscience in Biological Psychiatry: Blaming the Body. NY: Wiley & Sons. pp. 7–84. ISBN 978-0-471-00776-0.
  2. APA statement on Diagnosis and Treatment of Mental Disorders, American Psychiatric Association, September 26, 2003
  3. Most psychiatric disorders share a small number of genetic risk factors, VCU study shows, Virginia Commonwealth University
  4. Pickard BS, Malloy MP, Clark L, Lehellard S, Ewald HL, Mors O, Porteous DJ, Blackwood DH, Muir WJ (March 2005). "Candidate psychiatric illness genes identified in patients with pericentric inversions of chromosome 18". Psychiatric Genetics. 15 (1): 37–44. doi:10.1097/00041444-200503000-00007. PMID 15722956.
  5. Macgregor S, Visscher PM, Knott SA, Thomson P, Porteous DJ, Millar JK, Devon RS, Blackwood D, Muir WJ (December 2004). "A genome scan and follow-up study identify a bipolar disorder susceptibility locus on chromosome 1q42". Molecular Psychiatry. 9 (12): 1083–90. doi:10.1038/sj.mp.4001544. PMID 15249933.
  6. van Belzen MJ, Heutink P (2006). "Genetic analysis of psychiatric disorders in humans". Genes, Brain, and Behavior. 5 Suppl 2 (Suppl 2): 25–33. doi:10.1111/j.1601-183X.2006.00223.x. PMID 16681798.
  7. Meyer-Lindenberg A, Weinberger DR (October 2006). "Intermediate phenotypes and genetic mechanisms of psychiatric disorders". Nature Reviews. Neuroscience. 7 (10): 818–27. doi:10.1038/nrn1993. PMID 16988657.
  8. Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, Malloy MP, Chubb JE, Huston E, Baillie GS, Thomson PA, Hill EV, Brandon NJ, Rain JC, Camargo LM, Whiting PJ, Houslay MD, Blackwood DH, Muir WJ, Porteous DJ (November 2005). "DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling". Science. 310 (5751): 1187–91. Bibcode:2005Sci...310.1187M. doi:10.1126/science.1112915. PMID 16293762.
  9. Kates WR (April 2007). "Inroads to mechanisms of disease in child psychiatric disorders". The American Journal of Psychiatry. 164 (4): 547–51. doi:10.1176/appi.ajp.164.4.547. PMID 17403964.
  10. Van Gestel S, Van Broeckhoven C (October 2003). "Genetics of personality: are we making progress?". Molecular Psychiatry. 8 (10): 840–52. doi:10.1038/sj.mp.4001367. PMID 14515135.
  11. Lidz T, Blatt S (April 1983). "Critique of the Danish-American studies of the biological and adoptive relatives of adoptees who became schizophrenic". The American Journal of Psychiatry. 140 (4): 426–34. doi:10.1176/ajp.140.4.426. PMID 6837778.
  12. Joseph, Jay (2003). The Gene Illusion: Genetic Research in Psychiatry and Psychology Under the Microscope. New York, NY: Algora. ISBN 978-0-87586-344-3.
  13. Joseph, Jay (2006). The Missing Gene: Psychiatry, Heredity, and the Fruitless Search for Genes. NY: Algora Publishing. ISBN 978-0-87586-410-5.
  14. "Jay Joseph The Missing Gene". Archived from the original on 2009-04-17. Retrieved 2006-06-16.
  15. McEwen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, Fuchs E (March 2010). "The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation". Molecular Psychiatry. 15 (3): 237–49. doi:10.1038/mp.2009.80. PMC 2902200. PMID 19704408.
  16. McLaren, Niall (2007). Humanizing Madness. Ann Arbor, MI: Loving Healing Press. pp. 3–21. ISBN 978-1-932690-39-2.
  17. McLaren, Niall (2009). Humanizing Psychiatry. Ann Arbor, MI: Loving Healing Press. pp. 17–18. ISBN 978-1-61599-011-5.
  18. Sharfstein SS (August 2005). "Big Pharma and American Psychiatry: The Good, the Bad, and the Ugly". Psychiatric News. American Psychiatric Association. 40 (16): 3. Archived from the original on 19 November 2007.
  19. Dana J, Loewenstein G (July 2003). "A social science perspective on gifts to physicians from industry". JAMA. 290 (2): 252–5. doi:10.1001/jama.290.2.252. PMID 12851281.
  20. "Code on Interactions With Health Care Professionals". PhRMA. Retrieved 11 March 2018.
  21. Zipkin DA, Steinman MA (August 2005). "Interactions between pharmaceutical representatives and doctors in training. A thematic review". Journal of General Internal Medicine. 20 (8): 777–86. doi:10.1111/j.1525-1497.2005.0134.x. PMC 1490177. PMID 16050893.
  22. Huskamp HA, Donohue JM, Koss C, Berndt ER, Frank RG (2008). "Generic entry, reformulations and promotion of SSRIs in the US". PharmacoEconomics. 26 (7): 603–16. doi:10.2165/00019053-200826070-00007. PMC 2719790. PMID 18563951.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.